Top

Published in:

01-04-2020 | Lymphoma | Original Article

Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study

Authors: Veronica B. Ajewole, James E. Cox, Joshua T. Swan, Soumya G. Chikermane, Beverly Lamoth, Tomona Iso, Laura O. Okolo, Christen L. Ford, Amy M. Schneider, Eleanor C. Hobaugh, Kelty R. Baker

Published in: Supportive Care in Cancer | Issue 4/2020

Abstract

Purpose

Chemotherapy-induced peripheral neuropathy (CIPN) may necessitate chemotherapy dose reduction, delay, or discontinuation. This pilot study tested feasibility of patient enrollment, CIPN screening, and data collection in cancer patients for a future clinical study that will assess the safety and efficacy of an intervention that may prevent CIPN.

Methods

This prospective, observational, single-center, pilot study included adults with newly diagnosed lymphoma or multiple myeloma receiving neurotoxic chemotherapy. Patients were enrolled between September 2016 and February 2017. The Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire was completed by patients at 3 time points: baseline, week 6, and week 12. The primary outcome was change in the neurotoxicity score between these time points.

Results

Of 33 patients approached for consent, 28 (85%) provided consent and were enrolled. The FACT/GOG-Ntx questionnaire was completed by 28 (100%) at baseline, 25 (89%) at week 6, and 24 (86%) at week 12. Average (standard deviation) neurotoxicity scores were 36.5 (6.6) at baseline, 34.0 (8.3) at week 6, and 30.6 (7.6) at week 12. Neurotoxicity scores changed from baseline by − 2.7 points (95% CI − 5.5 to 0.1; p = 0.061) at week 6 and − 6.0 points (95% CI − 5.6 to − 0.8; p = 0.012) at week 12. Clinically meaningful declines (decrease of > 10% from baseline) in neurotoxicity score were detected in 36% (9 of 25) at week 6 and in 67% (16 of 24) at week 12.

Conclusion

Sixty-seven percent of patients experienced clinically significant CIPN within 12 weeks of starting chemotherapy. Feasibility metrics for enrollment, consent, CIPN assessment, and follow-up were met.

Majithia N, Temkin SM, Ruddy KJ, Beutler AS, Hershman DL, Loprinzi CL (2016) National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. Support Care Cancer 24(3):1439–1447. https://doi.org/10.1007/s00520-015-3063-4 CrossRefPubMed

Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, Colvin LA, Fallon M (2014) Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 155(12):2461–2470. https://doi.org/10.1016/j.pain.2014.09.020 CrossRefPubMed

Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F (2006) Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol 33(1):15–49. https://doi.org/10.1053/j.seminoncol.2005.12.010 CrossRefPubMed

Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63(6):419–437. https://doi.org/10.3322/caac.21204 CrossRefPubMed

Brewer JR, Morrison G, Dolan ME, Fleming GF (2016) Chemotherapy-induced peripheral neuropathy: current status and progress. Gynecol Oncol 140(1):176–183. https://doi.org/10.1016/j.ygyno.2015.11.011 CrossRefPubMed

Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB (2012) Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:1–10CrossRef

Cavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, Zara G, Plasmati R, Pastorelli F, Caraceni A, Pace A, Manicone M, Lissoni A, Colombo N, Bianchi G, Zanna C (2007) The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 12(3):210–215. https://doi.org/10.1111/j.1529-8027.2007.00141.x CrossRefPubMed

Velasco R, Bruna J (2010) Chemotherapy-induced peripheral neuropathy: an unresolved issue. Neurologia (Barcelona, Spain) 25(2):116–131CrossRef

Griffith KA, Couture DJ, Zhu S, Pandya N, Johantgen ME, Cavaletti G, Davenport JM, Tanguay LJ, Choflet A, Milliron T, Glass E, Gambill N, Renn CL, Dorsey SG (2014) Evaluation of chemotherapy-induced peripheral neuropathy using current perception threshold and clinical evaluations. Support Care Cancer 22(5):1161–1169. https://doi.org/10.1007/s00520-013-2068-0 CrossRefPubMed

10.

Bao T, Basal C, Seluzicki C, Li SQ, Seidman AD, Mao JJ (2016) Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk. Breast Cancer Res Treat 159(2):327–333. https://doi.org/10.1007/s10549-016-3939-0 CrossRefPubMedPubMedCentral

11.

Tofthagen C, Overcash J, Kip K (2012) Falls in persons with chemotherapy-induced peripheral neuropathy. Support Care Cancer 20(3):583–589. https://doi.org/10.1007/s00520-011-1127-7 CrossRefPubMed

12.

Zanville NR, Nudelman KN, Smith DJ, Von AD, McDonald BC, Champion VL, Saykin AJ (2016) Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment. Support Care Cancer 24(11):4779–4789. https://doi.org/10.1007/s00520-016-3329-5 CrossRefPubMedPubMedCentral

13.

Kazandjian D (2016) Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 43(6):676–681. https://doi.org/10.1053/j.seminoncol.2016.11.004 CrossRefPubMedPubMedCentral

14.

Palumbo A, Anderson K (2011) Multiple myeloma. N Engl J Med 364(11):1046–1060. https://doi.org/10.1056/NEJMra1011442 CrossRefPubMed

15.

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66(1):7–30. https://doi.org/10.3322/caac.21332 CrossRefPubMed

16.

Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443–459. https://doi.org/10.3322/caac.21357 CrossRefPubMed

17.

American Society of Clinical Oncology (2019) Multiple myeloma: statistics. https://www.cancer.net/cancer-types/multiple-myeloma/statistics. Accessed 29 Mar 2019

18.

Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP, Anderson KC (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127(2):165–172. https://doi.org/10.1111/j.1365-2141.2004.05188.x CrossRefPubMed

19.

Pal PK (1999) Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol 39(6):323–330PubMed

20.

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348(26):2609–2617. https://doi.org/10.1056/NEJMoa030288 CrossRefPubMed

21.

Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA (2006) Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 24(19):3113–3120. https://doi.org/10.1200/JCO.2005.04.7779 CrossRefPubMed

22.

Ropper AH, Gorson KC (1998) Neuropathies associated with paraproteinemia. N Engl J Med 338(22):1601–1607. https://doi.org/10.1056/NEJM199805283382207 CrossRefPubMed

23.

Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B (1999) Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341(21):1565–1571. https://doi.org/10.1056/NEJM199911183412102 CrossRefPubMed

24.

Trivedi MS, Hershman DL, Crew KD (2015) Management of chemotherapy-induced peripheral neuropathy. Am J Hematol-Oncol 11(1):4–10

25.

Curcio KR (2016) Instruments for assessing chemotherapy-induced peripheral neuropathy: a review of the literature. Clin J Oncol Nurs 20(2):144–151. https://doi.org/10.1188/16.cjon.20-01ap CrossRefPubMed

26.

Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, Cella D (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741–748PubMed

27.

Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer (Oxford, England : 1990) 46(3):479–494. https://doi.org/10.1016/j.ejca.2009.12.008 CrossRef

28.

Abbas ZG, Swai AB (1997) Evaluation of the efficacy of thiamine and pyridoxine in the treatment of symptomatic diabetic peripheral neuropathy. East Afr Med J 74(12):803–808PubMed

29.

Cakici N, Fakkel TM, van Neck JW, Verhagen AP, Coert JH (2016) Systematic review of treatments for diabetic peripheral neuropathy. Diabet Med 33(11):1466–1476. https://doi.org/10.1111/dme.13083 CrossRefPubMed

30.

Ziegler D, Low PA, Litchy WJ, Boulton AJ, Vinik AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus J, Schutte K, Dyck PJ (2011) Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 34(9):2054–2060. https://doi.org/10.2337/dc11-0503 CrossRefPubMedPubMedCentral

31.

Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi CL (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967. https://doi.org/10.1200/jco.2013.54.0914 CrossRefPubMed

32.

Huang HQ, Brady MF, Cella D, Fleming G (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17(2):387–393. https://doi.org/10.1111/j.1525-1438.2007.00794.x CrossRefPubMed

33.

Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, Olsen MR, Winfree KB, Chen J, Liu J, Guba SC, Socinski MA, Bonomi P (2015) Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Thorac Oncol 10(2):353–359. https://doi.org/10.1097/JTO.0000000000000277 CrossRefPubMed

34.

Stubblefield MD, Burstein HJ, Burton AW, Custodio CM, Deng GE, Ho M, Junck L, Morris GS, Paice JA, Tummala S, Von Roenn JH (2009) NCCN task force report: management of neuropathy in cancer. J Natl Compr Cancer Netw 7(Suppl 5):S1–S26 quiz S27-28

35.

Driessen CM, de Kleine-Bolt KM, Vingerhoets AJ, Mols F, Vreugdenhil G (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20(4):877–881. https://doi.org/10.1007/s00520-011-1336-0 CrossRefPubMed

Title: Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study
Authors: Veronica B. Ajewole
James E. Cox
Joshua T. Swan
Soumya G. Chikermane
Beverly Lamoth
Tomona Iso
Laura O. Okolo
Christen L. Ford
Amy M. Schneider
Eleanor C. Hobaugh
Kelty R. Baker
Publication date: 01-04-2020
Publisher: Springer Berlin Heidelberg
Keywords: Lymphoma
Multiple Myeloma
Cytostatic Therapy
Cancer Therapy
Published in: Supportive Care in Cancer / Issue 4/2020
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-019-05006-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2020

Health-related quality of life in Malaysian gastrointestinal cancer patients and their family caregivers—a comparison study

Reply to: Olanzapine: Sancho Panza for clinicians who care for patients with advanced cancer

Patient-reported outcomes in light of supportive medications in treatment-naïve lung cancer patients

Pain management index (PMI)—does it reflect cancer patients’ wish for focus on pain?

Factors influencing supportive care needs of multiple myeloma patients treated with chemotherapy

A systematic review examining nutrition support interventions in patients with incurable cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer